Recent research highlights the dual benefits of antidepressant therapy in patients suffering from both coronary artery disease (CAD) and depression, revealing important links between serotonin regulation, inflammation, and cardiac health.
A team of researchers explored the interplay between inflammation, serotonin (5-HT), and autonomic nervous system dysfunction in patients with myocardial infarction (MI) complicated by depression. Their study examined 280 CAD patients, tracking depressive symptoms, inflammatory markers, and cardiac outcomes over two years.
The findings revealed that CAD patients with depression exhibited significantly higher levels of inflammatory markers, including TNF-α, IL-4, IL-17, IFN-α, and IFN-γ, compared to those without depression. Importantly, patients receiving selective serotonin reuptake inhibitors (SSRIs) experienced fewer cardiac events, with only 3.7% experiencing events versus 11.8% in the untreated group.
Animal studies further confirmed these results. Mice undergoing MI surgery displayed both cardiac dysfunction and autonomic nervous system injury, which were worsened by excessive inflammation. Depressive behaviors were also observed, linked to inflammation in the cortex and hippocampus.
Treatment with fluoxetine or SN50 improved cardiac function, alleviated depressive behaviors, and reduced inflammation through the macrophages/TNF-α/TNFR/NF-κB signaling pathway. Experiments in serotonin transporter (SERT) knockout mice and H9C2 cardiac cells reinforced the relationship between 5-HT signaling and inflammation.
The study underscores the critical role of inflammation and autonomic nervous system dysfunction in the connection between MI and depression. Researchers concluded that antidepressant therapy not only alleviates depressive symptoms but also provides significant cardiac protection. Furthermore, targeting inflammation may represent a promising therapeutic approach for patients experiencing MI complicated by depression.
READ MORE
